M&A Deal Summary |
|
---|---|
Date | 2022-08-03 |
Target | KetaMD |
Sector | Healthcare Services |
Buyer(s) | Braxia Scientific |
Deal Type | Add-on Acquisition |
Deal Value | 6M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2018 |
Sector | Healthcare Services |
Revenue | 2M CAD (2023) |
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. The company is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. It seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Braxia Scientific was founded in 2018 and is based in Toronto, Ontario.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Healthcare Services) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Florida) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2022) | 1 of 1 |
Size (of disclosed) | 1 of 1 |